Immuneering To Participate In Upcoming Investor Conferences
Cantor Global Healthcare Conference (September 9-11 in New York City)
- Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET
H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)
- Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, September 14, 2026, from 5:00-5:30 pm ET
The fireside chats will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering's lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit .
Investor Contact:
Laurence Watts
New Street Investor Relations
...
Media Contact:
David Caouette
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment